Sotirios Lakis1, Vassiliki Kotoula2,3, Georgia-Angeliki Koliou4, Ioannis Efstratiou5, Sofia Chrisafi2, Alexios Papanikolaou6, Pantelis Zebekakis7, George Fountzilas2,8,9. 1. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece slakis@auth.gr. 2. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, Greece. 5. Department of Pathology, Papageorgiou Hospital, Thessaloniki, Greece. 6. First Department of Obstetrics and Gynecology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece. 7. First Department of Internal Medicine, AHEPA Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 8. Aristotle University of Thessaloniki, Thessaloniki, Greece. 9. German Oncology Center, Limassol, Cyprus.
Abstract
BACKGROUND/AIM: Ovarian cancer (OVCA) is characterized by genomic/molecular intra-patient heterogeneity (IPH). Tissue histology and morphological features are surrogates of the underlying genomic/molecular contexture. We assessed the morphological IPH of OVCA tumor compartments and of lymphocytic infiltrates in multiple matched samples per patient. MATERIALS AND METHODS: We examined 294 hematoxylin & eosin (H&E) OVCA tumor whole sections from 70 treatment-naïve patients who had undergone cytoreductive surgery. We assessed morphological subtypes as immunoreactive (IR), solid - proliferative (SD), papilloglandular (PG), and mesenchymal transition (MT); subtype load per patient; stromal tumor-infiltrating lymphocyte (sTIL) density as average per sample; and, as maximal sTIL values (max-TILs) among all samples per patient, ovaries and implants. RESULTS: Among all 294 tumor sections, the most frequent primary morphological subtype was PG (n=150, 51.0%), followed by MT (71, 24.1%), SD (48, 16.3%) and IR (15, 5.1%). Subtype combinations were observed in 67/294 sections (22.8%) and IPH in 48/70 patients (68.6%). PG prevailed in ovaries (p<0.001), SD and MT in implants (p=0.023 and p<0.001, respectively). sTILs were higher in SD compared to non-SD (p=0.019) and lower in PG, respectively (p<0.001). sTIL density was higher in implants than in ovaries (p<0.001). Higher max-TILs were associated with stage IV disease (p=0.043), upper abdominal dissemination (p=0.024), endometrioid histology (p=0.013), and grade 3 tumors (p=0.021). Favorable prognosticators were higher max-TILs per patient (PFS, OS) and higher SD-load (PFS). CONCLUSION: Clinically relevant morphological and host immune-response IPH appear to be the norm in OVCA. This may complicate efforts to decipher sensitivity of the tumor to certain treatment modalities from a single pre-operative biopsy. Copyright
BACKGROUND/AIM: Ovarian cancer (OVCA) is characterized by genomic/molecular intra-patient heterogeneity (IPH). Tissue histology and morphological features are surrogates of the underlying genomic/molecular contexture. We assessed the morphological IPH of OVCA tumor compartments and of lymphocytic infiltrates in multiple matched samples per patient. MATERIALS AND METHODS: We examined 294 hematoxylin & eosin (H&E) OVCA tumor whole sections from 70 treatment-naïve patients who had undergone cytoreductive surgery. We assessed morphological subtypes as immunoreactive (IR), solid - proliferative (SD), papilloglandular (PG), and mesenchymal transition (MT); subtype load per patient; stromal tumor-infiltrating lymphocyte (sTIL) density as average per sample; and, as maximal sTIL values (max-TILs) among all samples per patient, ovaries and implants. RESULTS: Among all 294 tumor sections, the most frequent primary morphological subtype was PG (n=150, 51.0%), followed by MT (71, 24.1%), SD (48, 16.3%) and IR (15, 5.1%). Subtype combinations were observed in 67/294 sections (22.8%) and IPH in 48/70 patients (68.6%). PG prevailed in ovaries (p<0.001), SD and MT in implants (p=0.023 and p<0.001, respectively). sTILs were higher in SD compared to non-SD (p=0.019) and lower in PG, respectively (p<0.001). sTIL density was higher in implants than in ovaries (p<0.001). Higher max-TILs were associated with stage IV disease (p=0.043), upper abdominal dissemination (p=0.024), endometrioid histology (p=0.013), and grade 3 tumors (p=0.021). Favorable prognosticators were higher max-TILs per patient (PFS, OS) and higher SD-load (PFS). CONCLUSION: Clinically relevant morphological and host immune-response IPH appear to be the norm in OVCA. This may complicate efforts to decipher sensitivity of the tumor to certain treatment modalities from a single pre-operative biopsy. Copyright
Authors: Fengju Chen; Yiqun Zhang; Don L Gibbons; Benjamin Deneen; David J Kwiatkowski; Michael Ittmann; Chad J Creighton Journal: Clin Cancer Res Date: 2018-02-09 Impact factor: 12.531
Authors: Allen W Zhang; Andrew McPherson; Katy Milne; David R Kroeger; Phineas T Hamilton; Alex Miranda; Tyler Funnell; Nicole Little; Camila P E de Souza; Sonya Laan; Stacey LeDoux; Dawn R Cochrane; Jamie L P Lim; Winnie Yang; Andrew Roth; Maia A Smith; Julie Ho; Kane Tse; Thomas Zeng; Inna Shlafman; Michael R Mayo; Richard Moore; Henrik Failmezger; Andreas Heindl; Yi Kan Wang; Ali Bashashati; Diljot S Grewal; Scott D Brown; Daniel Lai; Adrian N C Wan; Cydney B Nielsen; Curtis Huebner; Basile Tessier-Cloutier; Michael S Anglesio; Alexandre Bouchard-Côté; Yinyin Yuan; Wyeth W Wasserman; C Blake Gilks; Anthony N Karnezis; Samuel Aparicio; Jessica N McAlpine; David G Huntsman; Robert A Holt; Brad H Nelson; Sohrab P Shah Journal: Cell Date: 2018-05-10 Impact factor: 41.582
Authors: Lynn P Parker; Douglas D Taylor; Sarah Kesterson; Cicek Gercel-Taylor Journal: Cancer Genomics Proteomics Date: 2009 May-Jun Impact factor: 4.069
Authors: Matthew Schwede; Levi Waldron; Samuel C Mok; Wei Wei; Azfar Basunia; Melissa A Merritt; Constantine S Mitsiades; Giovanni Parmigiani; David P Harrington; John Quackenbush; Michael J Birrer; Aedín C Culhane Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-23 Impact factor: 4.254